The screen failure rate in a clinical trial is calculated by dividing the number of patients who were screened but not randomized (or not enrolled) by the total number of patients screened, then multiplying by 100 to get a percentage. If you screened 200 patients and 140 were randomized, your 60 screen failures give you a rate of 30%. The formula itself is straightforward, but in practice, deciding who counts as “screened” and understanding what the resulting number actually tells you about your trial is where things get complicated.
The Basic Formula and Its Variations
In its simplest form, the screen failure rate is: (Patients Screened − Patients Enrolled) ÷ Patients Screened × 100. Some sponsors calculate it slightly differently depending on the trial design. In trials with multiple screening stages, you might see separate failure rates calculated at each gate. A trial with a screening visit followed by a run-in period might report a “screening failure rate” for the first visit and a separate “run-in failure rate” for the second stage. For planning purposes, though, most people collapse these into a single number reflecting everyone who entered the screening pipeline but did not make it to randomization.
A persistent challenge with this calculation is that there is no universally standardized definition of what “screened” means. A research team that counts every patient who signed a screening consent form will get a different denominator than a team that counts only patients who completed the full battery of screening assessments. This inconsistency makes it difficult to compare screen failure rates across studies, because the starting line differs from trial to trial.1PubMed Central. Screen Failure Data in Clinical Trials: Are Screening Logs Worth It? If you are calculating your own rate, define clearly what triggers a patient’s entry into your denominator and stick with that definition across all sites.
Pre-Screening Versus Formal Screening
Before a patient ever shows up for a formal screening visit, many trial sites conduct an informal step called pre-screening. This is the process of looking through medical records, reviewing referral information, or having a brief conversation with a potential participant to gauge whether they are likely to meet the eligibility criteria.2Wiley Online Library (Journal of Evaluation in Clinical Practice). Pre‐Screening in Clinical Trials: Incentives, Behaviours, Consequences Pre-screened patients who are ruled out at this stage typically do not appear in the formal screening count and therefore do not factor into the screen failure rate calculation.
This distinction matters more than it might seem. A site that does thorough pre-screening will report a lower screen failure rate than a site that sends everyone straight to formal screening, even if both sites are drawing from the same patient population. When you see published screen failure rates, keep in mind that the number reflects the formal screening process and may not capture the full extent of patient attrition from the recruitment pipeline.
What Typical Screen Failure Rates Look Like
Across all therapeutic areas and trial phases, the average screen failure rate has been climbing. Data from a large benchmarking analysis found that the overall average increased to about 36%, up from roughly 35% several years earlier.3Applied Clinical Trials. Can Recruitment and Retention Get Any Worse? That average masks enormous variation by disease area, trial phase, and protocol complexity.
In oncology early-phase trials, screen failure rates at three major French cancer centers ranged from about 21% to 26%, with the leading reasons split among radiological findings, laboratory abnormalities, and clinical deterioration.4ESMO Open. Addressing screening failures in early-phase clinical trials in oncology: impact on patient outcomes and strategies for improvement In inflammatory bowel disease, one prospective study found a screen failure rate of about 18% among patients who consented to participate in phase IIb–III trials.5Oxford Academic. Analysis of Clinical Trial Screen Failures in Inflammatory Bowel Diseases: Real World Results from the International Organization for the study of IBD Meanwhile, lung cancer trials requiring biopsies with specific biomarker results had a screen failure rate close to 49%, compared with about 27% for trials without that biopsy requirement.6PubMed Central. Non-small cell lung cancer clinical trials requiring biopsies with biomarker-specific results for enrollment
The range is wide enough that a single “industry average” is not especially useful for planning your own trial. Your expected screen failure rate depends heavily on your therapeutic area, the complexity of your eligibility criteria, and whether your protocol demands invasive or time-consuming screening procedures. If you are writing a protocol for a biomarker-driven oncology study, a planning assumption of 25% would be dangerously optimistic. If you are running a straightforward trial in a well-characterized patient population, 35% might be too pessimistic.
Why Screen Failure Rates Keep Rising
The upward trend in screen failure rates is not random. It tracks closely with what has been happening to trial protocols themselves. Over the past two decades, protocols have become substantially more restrictive. The number of eligibility criteria per protocol has grown, the criteria have become more complex, and the operational bar for demonstrating eligibility has risen. In inflammatory bowel disease trials, for instance, eligibility requirements have become so stringent that it is often hard to identify qualifying patients even in specialized centers. The introduction of central reading for endoscopic severity around 2012 added another layer, with failure to meet endoscopic thresholds becoming a leading cause of screen failures.7Journal of Crohn’s and Colitis. Declining Enrolment and Other Challenges in IBD Clinical Trials: Causes and Potential Solutions
A longitudinal analysis of protocol design from 2004 to 2025 found that enrollment targets have stayed roughly flat even as eligibility criteria have tightened considerably. The natural consequence of narrowing the eligible pool without increasing screening volume is a higher failure rate. ClinicalTrials.gov does not directly record screen failures, but the pattern aligns with rising trial durations reported across the literature.8Applied Clinical Trials. Two Decades of Rising Protocol Complexity: A Longitudinal Analysis of Clinical Trial Design Evolution, 2004–2025 In liver disease trials for metabolic dysfunction-associated steatohepatitis, a pooled analysis confirmed that screen failure rates have increased over time and correlate with the number of trial sites and the global reach of the study.9American Journal of Gastroenterology. Enrollment in Metabolic Dysfunction-Associated Steatohepatitis Clinical Trials: A Pooled Analysis of Screen Failure Rates
The reasons individual patients fail screening vary by disease, but they tend to cluster around a few themes: not meeting a laboratory or imaging threshold, clinical deterioration between referral and the screening visit, withdrawal of consent, and administrative or logistical problems. In oncology early-phase trials, radiological findings, biological abnormalities (particularly organ dysfunction), and declining performance status together accounted for the majority of failures.4ESMO Open. Addressing screening failures in early-phase clinical trials in oncology: impact on patient outcomes and strategies for improvement In biomarker-driven lung cancer trials, worsening performance status was responsible for over half of screen failures among patients who were biomarker-eligible.6PubMed Central. Non-small cell lung cancer clinical trials requiring biopsies with biomarker-specific results for enrollment
The Financial Weight of Screen Failures
Every patient who enters formal screening but does not enroll represents real costs: site staff time, laboratory tests, imaging, data management, and sometimes invasive procedures. Benchmarking data suggest that screen failures account for roughly 11% of total trial costs.10PubMed Central. Assessing the Financial Value of Decentralized Clinical Trials In absolute terms, that percentage can translate to millions of dollars.
A cost-modeling study of a phase 3 hospital-acquired pneumonia trial illustrated the sensitivity vividly. In their model, reducing the number of patients who needed to be screened to randomize a single patient from 100 down to 90 dropped the per-patient cost by roughly $5,700, which across the full trial amounted to about $5.7 million in savings.11Clinical Infectious Diseases. Cost Drivers of a Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia Phase 3 Clinical Trial Of all the cost drivers they examined, the screen failure rate yielded the largest variation in overall trial expense. That finding is worth internalizing: screen failure rate is not just a recruitment metric, it is one of the most powerful levers on your budget.
Costs also accumulate indirectly through extended timelines. A gonorrhea treatment trial found that eligibility criteria linked to specific protocol amendments excluded patients who would otherwise have qualified. If those patients had been enrollable, the trial would have reached its enrollment target 74 days sooner, avoiding an estimated $130,000 in additional costs, about 15% of the recruitment and follow-up budget.12PubMed Central. Impact of eligibility criteria on participant enrollment for a randomized clinical trial of gonorrhea treatment
Strategies That Actually Reduce Screen Failures
The most effective lever is also the most upstream: designing eligibility criteria with real-world patient data rather than copying criteria from prior protocols and adding more restrictions on top. The Clinical Trials Transformation Initiative recommends using real-world data to pressure-test assumptions about eligibility criteria before the protocol is finalized, focusing analytical effort on the criteria with the greatest impact on feasibility and generalizability.13PubMed Central. Real-World Data for Planning Eligibility Criteria and Enhancing Recruitment: Recommendations from the Clinical Trials Transformation Initiative The practical recommendation is direct: avoid making eligibility decisions based solely on precedent and assumptions.14CTTI Recommendations: Use of Real-World Data to Plan Eligibility Criteria and Enhance Recruitment. CTTI Recommendations: Use of Real-World Data to Plan Eligibility Criteria and Enhance Recruitment
Once a trial is underway, protocol amendments can help. Research on amendment practices found that protocols with at least one amendment were more effective at increasing screening volume and aligning actual enrollment closer to planned targets.15PubMed. New Benchmarks on Protocol Amendment Practices, Trends and their Impact on Clinical Trial Performance Amendments that relax overly restrictive criteria or remove requirements that are generating failures without protecting patient safety can meaningfully move the needle. The trade-off is that amendments themselves cost time and money, so catching problematic criteria at the design stage is always preferable.
Electronic medical record-based pre-screening is another approach gaining traction. In one ophthalmology trial, structured EMR data was used to identify and invite patients who were highly likely to meet all eligibility criteria. Of the 48 patients who attended formal screening, every single one met all the criteria, and 47 of the 48 were successfully enrolled.16Eye. Leveraging structured EMR data for efficient patient prescreening: a practical approach to reducing screen-failure rates in Light Touch Trial That is an extraordinary result, and while it depended on having well-structured data for a condition whose eligibility markers are readily captured in EMRs, it demonstrates the potential of rigorous pre-screening to cut failures to near zero.
Decentralized clinical trial methods also appear to help. A financial analysis compared screen failure rates in trials using decentralized elements against traditional trials and found lower failure rates across both phase II and phase III. For phase II, the average rate dropped from about 32% in traditional trials to about 24% in decentralized ones. For phase III, it fell from about 30% to about 20%.10PubMed Central. Assessing the Financial Value of Decentralized Clinical Trials The mechanism likely involves broader geographic reach and reduced logistical burden on patients, both of which help retain people through the screening process who might otherwise drop out or deteriorate while waiting for a site visit.
Reporting Screen Failures in Published Trials
The CONSORT flow diagram, which is the standard for reporting participant flow in randomized trials, calls for the number of patients assessed for eligibility, the number excluded before randomization, and the reasons for exclusion. In practice, reporting has been inconsistent. A review of published randomized trials found that about 81% reported the overall number assessed for eligibility and 71% reported the number excluded before randomization, but the specific reasons for exclusion were more poorly documented.17PubMed Central. Reporting of participant flow diagrams in published reports of randomized trials
If you are calculating a screen failure rate from a published trial’s flow diagram, the math is simple enough: take the number assessed for eligibility as your denominator, subtract the number randomized, and divide the difference by the denominator. But be aware that the flow diagram may not capture everyone who was pre-screened or informally evaluated before the formal eligibility assessment. Your calculated rate reflects only what the investigators chose to report as their starting denominator, which, as noted earlier, varies from study to study.
For your own trial, the best practice is to define “screened” explicitly in your statistical analysis plan and site training materials, record reasons for every screen failure in a screening log, and report both the rate and the reason breakdown in your results. Regulatory agencies and journal reviewers increasingly expect this level of detail, and it is invaluable for planning future trials in the same therapeutic area.
Screen Failures and Diversity in Clinical Trials
Screen failure rates do not affect all patients equally, and this is where the metric connects to broader questions about who gets to participate in clinical research. A study of adults recruited for a preclinical Alzheimer disease trial found that Hispanic and non-White participants were excluded at screening more frequently than White participants. About 40% of Hispanic participants were excluded compared with about 26% of White participants. After adjusting for other factors, Black, Hispanic, and Asian participants all had significantly lower odds of being eligible to proceed past the first screening visit.18JAMA Network Open. Disparities by Race and Ethnicity Among Adults Recruited for a Preclinical Alzheimer Disease Trial
The reasons behind these disparities are complex and likely include differences in comorbidity burden, access to the types of care that produce the medical documentation trials require, and eligibility criteria that may inadvertently select against certain populations. When a protocol requires, say, a recent MRI of a specific type, or a particular range on a laboratory value that correlates with socioeconomic access to healthcare, the screen failure machinery can amplify existing health disparities. This does not mean the criteria are medically unnecessary, but it does mean that screen failure analysis broken down by demographics can reveal patterns that merit a careful second look at whether each criterion is truly essential to the science.
For sponsors tracking screen failure rates, disaggregating the data by race, ethnicity, age, and sex is an increasingly important step. A high overall screen failure rate is a problem for timelines and budgets. A disproportionately high rate in specific demographic groups is a problem for the generalizability of the trial’s results and, ultimately, for the equity of the therapies it produces.
When Screen Failure Rate Itself Can Mislead
A low screen failure rate is generally considered desirable, but it does not automatically mean a trial is performing well. A site that aggressively pre-screens patients before consenting them for formal screening will report a low failure rate, but the effort and cost of that pre-screening may simply be hidden upstream. Conversely, a site that casts a wide net and screens liberally might report a higher failure rate but actually be doing a better job of identifying patients who would not otherwise come to clinical attention.
There is also a tension between screen failure rates and enrollment speed. A protocol with very broad eligibility criteria will have a low screen failure rate but may enroll patients whose variability dilutes the treatment signal, requiring a larger sample size. A protocol with tight criteria will have a higher failure rate but may need fewer patients to detect an effect. The screen failure rate is one metric among several that together tell you whether your trial is on track. It is most useful in combination with enrollment rate, screen-to-randomize time, and the reason-for-failure breakdown.
Finally, the lack of a standardized definition of “screened” across the industry means that comparing your screen failure rate to published benchmarks requires caution. A rate of 30% at your sites and a rate of 30% reported in a literature benchmark may not reflect the same thing if the two used different denominators. When benchmarking, pay attention to how the comparator study defined its screening population. If that detail is not reported, treat the comparison as approximate rather than precise.